USC scientists engineer self-renewing immune cells to sustain anti-tumour attack

Researchers at the University of Southern California have developed a method to produce a sustained supply of genetically engineered immune cells capable of targeting tumours. Rather than modifying mature immune cells — the conventional starting point for therapies such as CAR-T — the team worked with immature progenitor cells, which retain the capacity to proliferate and differentiate inside the body.

The approach, reported via ScienceDaily from USC, is designed to overcome one of the central challenges in adoptive cell therapy: that populations of engineered mature T cells tend to become exhausted or fail to persist long term after infusion. By engineering cells earlier in their developmental trajectory, the researchers argue the body can be induced to generate tumour-reactive cells on an ongoing basis.

Full methodological detail and peer-review status were not available at the time of writing; the ScienceDaily summary does not link to a published journal article. The work appears to involve genetic modification of progenitor cells, though the specific gene-editing platform and target antigens are not described in public reporting.

This is an early-stage research finding. No clinical data in human patients have been reported, and the pathway from laboratory discovery to any eventual clinical application involves multiple further stages of development and regulatory evaluation.